The abstract is read at the publisher; the summary is JClub's.
KRAS inhibition with panRAS-ON or panKRAS-off remodels the KRAS interactome, altering 16.5% of KRAS-proximal proteins while producing highly correlated changes despite distinct inhibitor mechanisms.
- Why it matters: Clinical KRAS inhibitors differ in specificity and mechanism, yet how they reshape the KRAS signaling network and downstream migration programs is not fully defined.
- What they did: Using Proximity-dependent Biotin Identification, the study mapped KRAS-proximal proteins after treatment with panRAS-ON (cyclophilin–RAS ternary complex in the GTP-bound state) or panKRAS-off (switch II pocket binding), then assessed Afadin phosphorylation and function.
- The result: Afadin was highly affected; KRAS inhibition sufficiently abolished EGF-mediated AFDN phosphorylation, and AFDN silencing in a KRAS-driven non-small cell lung cancer model blocked chemotaxis and disrupted directional migration in an EGF-driven wound healing assay.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.